Mycosis Fungoides - Epidemiology Forecast to 2028
Markets Covered
United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2016-2028
Mycosis Fungoides Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Mycosis Fungoides in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders views are also taken into account to provide a deep understanding of the Mycosis Fungoides outlook. It also includes the explanation of changing trends of epidemiology outlining the Mycosis Fungoides scenario.
Mycosis Fungoides Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Mycosis Fungoides thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.
Report Scope
The report covers detailed overview of Mycosis Fungoides explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
The Mycosis Fungoides Report assesses the disease risk and burden and highlights the unmet needs
It also helps to recognize the growth opportunities in the 7MM with respect to the patient population
Key strengths
10 Year Forecast
7MM Coverage
Total Cases in Mycosis Fungoides
Key assessments
Patient Segmentation in Mycosis Fungoides
Mycosis Fungoides Risk & Burden
Factors driving growth in a specific Mycosis Fungoides patient population
2. Mycosis Fungoides Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Mycosis Fungoides in 2016
2.2. Patient Share Distribution of Mycosis Fungoides in 2028
3. Disease Background and Overview: Mycosis Fungoides
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Mycosis Fungoides in 7MM
4.3. Total Prevalent/ Incident Patient Population of Mycosis Fungoides in 7MM By Countries
5. Epidemiology of Mycosis Fungoides by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Mycosis Fungoides
5.1.3. Sub-Type Specific cases of the Mycosis Fungoides *
5.1.4. Sex- Specific Cases of the Mycosis Fungoides *
5.1.5. Diagnosed Cases of the Mycosis Fungoides
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Mycosis Fungoides
5.4.3. Sub-Type Specific cases of the Mycosis Fungoides *
5.4.4. Sex- Specific Cases of the Mycosis Fungoides *
5.4.5. Diagnosed Cases of the Mycosis Fungoides
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Mycosis Fungoides
5.5.3. Sub-Type Specific cases of the Mycosis Fungoides *
5.5.4. Sex- Specific Cases of the Mycosis Fungoides *
5.5.5. Diagnosed Cases of the Mycosis Fungoides
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Mycosis Fungoides
5.6.3. Sub-Type Specific cases of the Mycosis Fungoides *
5.6.4. Sex- Specific Cases of the Mycosis Fungoides *
5.6.5. Diagnosed Cases of the Mycosis Fungoides
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Mycosis Fungoides
5.7.3. Sub-Type Specific cases of the Mycosis Fungoides *
5.7.4. Sex- Specific Cases of the Mycosis Fungoides *
5.7.5. Diagnosed Cases of the Mycosis Fungoides
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Mycosis Fungoides
5.8.3. Sub-Type Specific cases of the Mycosis Fungoides *
5.8.4. Sex- Specific Cases of the Mycosis Fungoides *
5.8.5. Diagnosed Cases of the Mycosis Fungoides
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Mycosis Fungoides
5.9.3. Sub-Type Specific cases of the Mycosis Fungoides *
5.9.4. Sex- Specific Cases of the Mycosis Fungoides *
5.9.5. Diagnosed Cases of the Mycosis Fungoides
6. Unmet Needs of the Mycosis Fungoides
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
List Of Tables
Table 1: Total Prevalent/Incident Cases of the Mycosis Fungoides in 7MMTable 2: Total Prevalent/Incident Cases of the Mycosis Fungoides in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Mycosis Fungoides in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Mycosis Fungoides in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Mycosis Fungoides in United States (2016-2028)*
Table 6: Diagnosed Cases of the Mycosis Fungoides in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Mycosis Fungoides in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Mycosis Fungoides in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Mycosis Fungoides in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Mycosis Fungoides in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Mycosis Fungoides in France (2016-2028)
Table 12: Sub-Type Specific cases of the Mycosis Fungoides in France (2016-2028) *
Table 13: Sex- Specific Cases of the Mycosis Fungoides in France (2016-2028) *
Table 14: Diagnosed Cases of the Mycosis Fungoides in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Mycosis Fungoides in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Mycosis Fungoides in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Mycosis Fungoides in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Mycosis Fungoides in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Mycosis Fungoides in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Mycosis Fungoides in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Mycosis Fungoides in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Mycosis Fungoides in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Mycosis Fungoides in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Mycosis Fungoides in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Mycosis Fungoides in UK (2016-2028) *
Table 26: Diagnosed Cases of the Mycosis Fungoides in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Mycosis Fungoides in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Mycosis Fungoides in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Mycosis Fungoides in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Mycosis Fungoides in Japan (2016-2028)
List Of Figures
Figure 1: Total Prevalent/Incident Cases of the Mycosis Fungoides in 7MMFigure 2: Total Prevalent/Incident Cases of the Mycosis Fungoides in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Mycosis Fungoides in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Mycosis Fungoides in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Mycosis Fungoides in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Mycosis Fungoides in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Mycosis Fungoides in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Mycosis Fungoides in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Mycosis Fungoides in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Mycosis Fungoides in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Mycosis Fungoides in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Mycosis Fungoides in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Mycosis Fungoides in France (2016-2028) *
Figure 14: Diagnosed Cases of the Mycosis Fungoides in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Mycosis Fungoides in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Mycosis Fungoides in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Mycosis Fungoides in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Mycosis Fungoides in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Mycosis Fungoides in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Mycosis Fungoides in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Mycosis Fungoides in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Mycosis Fungoides in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Mycosis Fungoides in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Mycosis Fungoides in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Mycosis Fungoides in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Mycosis Fungoides in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Mycosis Fungoides in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Mycosis Fungoides in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Mycosis Fungoides in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Mycosis Fungoides in Japan (2016-2028)
Coccidioidomycosis (Infectious Disease) - Drugs In Development, 2021
Coccidioidomycosis (Infectious Disease) - Drugs In Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis (Infectious Disease) - Drugs In Development, 2021, provides an overview of the
USD 2000 View ReportTransformed Mycosis Fungoides (Oncology) - Drugs in Development, 2021
Transformed Mycosis Fungoides (Oncology) - Drugs in Development, 2021Transformed Mycosis Fungoides (Oncology) - Drugs in Development, 2021 provides an overview of the Transformed Mycosis Fungoides pipeline landscape.The report provides comprehensive
USD 2000 View ReportTransformed Mycosis Fungoides (Oncology) - Drugs in Development, 2021
Transformed Mycosis Fungoides (Oncology) - Drugs in Development, 2021Transformed Mycosis Fungoides (Oncology) - Drugs in Development, 2021 provides an overview of the Transformed Mycosis Fungoides pipeline landscape.The report provides comprehensive
USD 2000 View ReportMycosis Fungoides (Oncology) - Drugs in Development, 2021
Mycosis Fungoides (Oncology) - Drugs in Development, 2021Mycosis Fungoides (Oncology) - Drugs in Development, 2021 provides an overview of the Mycosis Fungoides pipeline landscape.The report provides comprehensive information on the
USD 2000 View ReportFill The Form For Sample Request